Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

New Agents and Evolving Strategies in Prostate Cancer: Focus on Castration-Sensitive Disease
  • CME

Credits Available
Physicians: maximum of 1.5 AMA PRA Category 1 Credits
Released: March 14, 2022 Expiration: March 13, 2023
Start Activity
Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
Myovant Sciences, Inc.
Pfizer, Inc.
Atish Choudhury, MD, PhD
Michael S. Cookson, MD, MMHC, FACS
David F. Jarrard, MD

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Compare the mechanism of action, cardiovascular risk, and overall toxicity profiles associated with all approved systemic therapies for CSPC
  • Apply cardioprotective strategies to reduce risk in patients with prostate cancer receiving ADT
  • Plan optimal, individualized sequential therapeutic strategies for nonmetastatic or metastatic CSPC, considering all available agents, clinical data, and expert recommendations
  • Counsel patients on available therapies, taking into consideration patient preferences and comorbidities regarding differences in administration and safety profiles

Information on this Educational Activity

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Faculty

Michael S. Cookson, MD, MMHC, FACS

Professor and Chair
Department of Urology
The University of Oklahoma Health Sciences Center, College of Medicine
Urologic Oncologist
OU Health Stephenson Cancer Center, Prostate & Urologic Cancers Clinic
OU Health
Oklahoma City, Oklahoma

Michael S. Cookson, MD, MMHC, FACS, has disclosed that he has received consulting fees from Astellas, Bayer, Janssen, Merck, Myovant Sciences, Pacific Edge Diagnostics, Prokarium, Propella, and TesoRx; funds for research support from Bayer HealthCare AG and Ferring; and other fees (reviewer of abstracts) from BioPharm Communications.
Atish Choudhury, MD, PhD

Assistant Professor of Medicine
Department of Medicine
Harvard Medical School
Senior Physician
Medical Oncology
Lank Center for Genitourinary Oncology
Dana-Farber Cancer Institute
Boston, Massachusetts

Atish Choudhury, MD, PhD, has disclosed that he has received consulting fees from Astellas, AstraZeneca, Bayer, Blue Earth, and Lilly.
David F. Jarrard, MD

Professor and Vice Chair
Department of Urology
John P. Livesey Chair in Urologic Oncology
Associate Director for Translational Research
Carbone Cancer Center
University of Wisconsin School of Medicine and Public Health
Madison, Wisconsin

David F. Jarrard, MD, has no relevant conflicts of interest to report.

Staff

Kemi Obajimi, PhD

Scientific Director

Kemi Obajimi, PhD, has no relevant conflicts of interest to report.
Kristen Rosenthal, PhD

Senior Scientific Director

Kristen Rosenthal, PhD, has no relevant conflicts of interest to report.
Rachael M. Andrie, PhD

Scientific Director

Rachael M. Andrie, PhD, has no relevant conflicts of interest to report.
Shara Pantry, PhD

Associate Scientific Director

Shara Pantry, PhD, has no relevant conflicts of interest to report.
Timothy A. Quill, PhD

Associate Director, Scientific Services

Timothy A. Quill, PhD, has no relevant conflicts of interest to report.
Jim Mortimer

Senior Director, Oncology Programs and Partnership Development

Jim Mortimer has no relevant conflicts of interest to report.
Kevin Obholz, PhD

Senior Director, Educational Strategy

Kevin Obholz, PhD, has no relevant conflicts of interest to report.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Target Audience

This program is intended for oncologists and other healthcare professionals who care for patients with prostate cancer.

Goal

The goal of this activity is to improve the knowledge, confidence, and competence of learners to integrate new agents and recent findings into the treatment of patients with prostate cancer.

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Program Medium

This program has been made available online.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 1.5 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from March 14, 2022, through March 13, 2023:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

New Agents and Evolving Strategies in Prostate Cancer: Focus on Castration-Sensitive Disease
  • CME

Loading...
In this on-demand webcast from a live webinar, Michael S. Cookson, MD, MMHC, FACS; David F. Jarrard, MD; and Atish Choudhury, MD, PhD, review the current data on managing castration-sensitive prostate cancer including data from the 2022 ASCO Genitourinary Cancers Symposium.
Atish Choudhury, MD, PhD
Michael S. Cookson, MD, MMHC, FACS
David F. Jarrard, MD
Physicians: maximum of 1.5 AMA PRA Category 1 Credits
Released: March 14, 2022 Expiration: March 13, 2023

Related Content

Downloadable slideset from Eric Jonasch, MD on managing treatment-related adverse events for patients with RCC, from Clinical Care Options (CCO).

Eric Jonasch, MD Released: June 5, 2022

Downloadable slideset from Katy E. Beckermann, MD, PhD on the selection and sequencing of therapy for patients with advanced RCC after progression on first-line therapy, from Clinical Care Options (CCO).

Katy E. Beckermann, MD, PhD Released: June 5, 2022

Downloadable slideset from Naomi B. Haas, MD on adjuvant approaches and first line treatment options for patients with RCC, from Clinical Care Options (CCO).

person default Naomi B. Haas, MD Released: June 5, 2022

Clinical Care Options (CCO): Dr Heather Cheng answers audience questions from a live symposium on current and expanding role of PARP inhibitors in prostate cancer care

Heather H. Cheng, MD, PhD Released: April 26, 2022
Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
Myovant Sciences, Inc.
Pfizer, Inc.

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings